Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;40(5):869-880.
doi: 10.1002/mds.30179. Epub 2025 Mar 18.

Treatment for Dyskinesia in Parkinson's Disease: A Network Meta-analysis of Randomized Controlled Trials

Rui Yan  1   2 , Xiaoqing Zheng  1   2 , Yixuan Yin  1   2 , Junjiao Zhang  1   2 , Yusha Cui  1   2 , Dongning Su  1   2 , Zhirong Wan  3 , Tao Feng  1   2
Affiliations

Treatment for Dyskinesia in Parkinson's Disease: A Network Meta-analysis of Randomized Controlled Trials

Rui Yan et al. Mov Disord. 2025 May.

Abstract

Background: Dyskinesia is a motor complication of Parkinson's disease (PD) posing therapeutic challenges. The optimal therapy for dyskinesia in PD has not been identified due to the lack of comprehensive evaluation of treatments.

Objective: The aim was to compare the efficacy and safety of interventions for alleviating levodopa-induced dyskinesia in PD.

Methods: We conducted a Bayesian network meta-analysis (NMA) by systematically searching PubMed, Web of Science, Embase, Cochrane Library, ClinicalTrials.gov, and EudraCT databases up to April 1, 2024. The primary efficacy outcome was the change in scores on dyskinesia rating scales from baseline.

Results: The study included 85 randomized controlled trials (RCT) involving 13,826 PD patients, comprising 39 interventions. Nine treatments were significantly more effective in reducing scores on dyskinesia rating scales than control (placebo, sham surgery, sham repetitive transcranial magnetic stimulation, or best medical treatment). Globus pallidus interna deep brain stimulation (GPi-DBS) had the highest probability to be the most effective (standardized mean difference, 95% credible interval: -1.27, -1.65 to -0.88; surface under the cumulative ranking curve [SUCRA]: 97.4%), followed by levodopa-carbidopa intestinal gel infusion (SUCRA = 89.7%), subthalamic nucleus (STN)-DBS (SUCRA = 89%), immediate-release (IR) amantadine (SUCRA = 86.5%), pallidotomy (SUCRA = 84.9%), ADS-5102 (SUCRA = 82.9%), clozapine (SUCRA = 77.2%), OS320 (SUCRA = 64.8%), and AFQ056 (SUCRA = 54.5%). GPi-DBS was superior to STN-DBS, and pallidotomy ranked higher than subthalamotomy. ADS-5102 and OS320 had higher adverse event (AE) rates compared to control, whereas AFQ056 and ADS-5102 were linked to more serious AEs.

Conclusions: This RCT-based NMA identifies and ranks nine efficacious interventions for dyskinesia in PD. GPi-DBS may be the most effective therapy for treating dyskinesia, with IR amantadine ranking highest among oral medications. Novel anti-dyskinetic medications are associated with less-favorable tolerance profiles. © 2025 International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; dyskinesia; movement disorder; network meta‐analysis; randomized controlled trials.

PubMed Disclaimer

References

    1. Zhu J, Cui Y, Zhang J, et al. Temporal trends in the prevalence of Parkinson's disease from 1980 to 2023: a systematic review and meta‐analysis. Lancet Healthy Longev 2024;5(7):e464–e479. https://doi.org/10.1016/S2666-7568(24)00094-1
    1. Ahlskog JE, Muenter MD. Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16(3):448–458.
    1. Kim HJ, Mason S, Foltynie T, Winder‐Rhodes S, Barker RA, Williams‐Gray CH. Motor complications in Parkinson's disease: 13‐year follow‐up of the CamPaIGN cohort. Mov Disord 2020;35(1):185–190.
    1. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005;20(2):224–230.
    1. Daneault JF, Carignan B, Sadikot AF, Panisset M, Duval C. Drug‐induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia? BMC Med 2013;11:76.

Publication types

MeSH terms

LinkOut - more resources